1. Home
  2. Companies
  3. PTX
  4. Material Events

Prescient Therapeutics (ASX:PTX) — Material Events

ASX:PTX · 12 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 10 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
10
Prescient Therapeutics Advances PTX-100 with EMA Orphan Drug Status and Global Trial ExpansionMedium
Prescient Therapeutics secures EMA orphan drug status for PTX-100, advances Phase 2a CTCL trial with global site expansion
30 Jan 2026 ·Quarterly Activities Report and Appendix 4C ·85
Prescient Secures EMA Orphan Drug Status for PTX-100 in CTCLMedium
Prescient Therapeutics secures EMA Orphan Drug Designation for PTX-100 in CTCL
19 Nov 2025 ·Regulatory Announcement ·85
Prescient Therapeutics Advances PTX-100 Phase 2a Trial, Reduces Loss by 4.4%, Raises $9.8MMedium
Prescient Therapeutics advances PTX-100 Phase 2a trial, reduces loss by 4.4%, raises $9.8M
21 Aug 2026 ·Preliminary Final Report and Annual Report ·85
Prescient Therapeutics Gains EU Nod to Launch PTX-100 Phase 2a Trial in CTCLMedium
Prescient Therapeutics Secures EU Approval to Start PTX-100 Phase 2a Trial for CTCL
15 Dec 2025 ·Clinical Trial Announcement ·80
Prescient secures $6 million to carry PTX-100 beyond December reviewMedium
Prescient Therapeutics completes circa $6 million raise to fund PTX-100 development
23 Sept 2026 ·Capital Raising ·78
Prescient reaches PTX-100 review threshold as cash rises to A$11.8 millionMedium
Prescient reaches PTX-100 trial milestone and secures $6.0 million capital raise
13 Oct 2026 ·Quarterly Activities Report and Appendix 4C ·78
Prescient Therapeutics Targets $7 Million SPP to Propel PTX-100 DevelopmentMedium
Prescient Therapeutics launches $7 million Share Purchase Plan to advance PTX-100 cancer therapy
25 Aug 2026 ·Capital Raising ·75
Prescient Therapeutics Advances PTX-100 Trials Amid Rising Losses and $9.85M Capital RaiseMedium
Prescient Therapeutics reports increased half-year loss, advances PTX-100 clinical trials, raises $9.85M capital
24 Feb 2026 ·Appendix 4D Half-year report ·75
Prescient Therapeutics Launches $7 Million SPP to Propel PTX-100 DevelopmentMedium
Prescient Therapeutics launches $7 million Share Purchase Plan to advance PTX-100 clinical development
26 Aug 2026 ·Capital Raising ·75
Prescient Therapeutics Accelerates PTX-100 Trial Enrolment and Appoints New Chief Medical OfficerMedium
Prescient Therapeutics advances PTX-100 Phase 2a trial with increased enrolment and new CMO appointment
27 July 2026 ·Quarterly Activities Report and Appendix 4C ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.